VERACYTE, INC.VCYT

Market cap

$3.3B

P/E ratio

	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Testing revenue	-	-	-	-	-	-	107	102	188	251	327	419
Product revenue	-	-	-	-	-	-	1	10	11	13	16	14
Biopharmaceutical and other revenue	-	-	-	-	-	-	-	-	20	33	19	13
Total revenue	-	-	-	-	-	92	120	117	220	297	361	446
Testing revenue	-	-	-	-	-	-	-	36	59	75	89	115
Product revenue	-	-	-	-	-	-	-	5	6	8	9	9
Biopharmaceutical and other revenue	-	-	-	-	-	-	-	-	10	18	15	12
Cost of revenue	13	17	21	25	28	33	36	-	-	-	-	-
Cost, Amortization	-	-	-	-	-	-	-	-	-	-	-	12
Total cost of revenue	-	-	-	-	-	-	-	-	-	-	-	148
Gross profit	-	-	-	-	-	-	-	-	-	-	-	298
Research and development	8	10	13	15	14	15	15	17	30	41	57	69
Selling and marketing	13	22	25	28	32	41	54	52	80	98	101	95
General and administrative	12	19	23	24	23	24	29	37	101	77	86	111
Impairment of long-lived assets	-	-	-	-	-	-	-	-	-	-	68	3
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	3
Total operating expenses	-	-	-	-	-	-	135	153	301	338	447	282
Income (loss) from operations	-23	-29	-33	-29	-27	-22	-15	-35	-82	-41	-86	16
Other income, net	-2	0	0	0	0	1	3	1	0	5	9	10
Income (loss) before income taxes	-	-	-	-	-	-	-	-	-82	-36	-77	26
Income Tax Expense (Benefit)	-	-	-	-	-	-	-	-	-6	0	-2	2
Net income (loss)	-	-	-	-	-	-	-	-35	-76	-37	-74	24
Basic (in USD per share)	-	-	-	-	-	-	-	-	-1.11	-0.51	-1.02	0.32
Diluted (in USD per share)	-	-	-	-	-	-	-	-	-1.11	-0.51	-1.02	0.31